The University of Vermont is about to start a first-in-human trial of a new kind of treatment for malignant mesothelioma. The new approach involves a drug called RSO-021. The drug works differently from other cancer therapies. It blocks the ability of cancer cells to manage their own waste products. It’s developers say the new treatment for malignant mesothelioma aims to kill cancer cells from the inside out. The concept for RSO-021 was first developed at the University of Vermont. Scientists at Wake Forest University School of Medicine and the UK biotech company RS Oncology have tested the drug in mice with promising results. Human trials of RSO-021 will start soon in the UK. US patients will be recruited in 2022. … Continue reading New Treatment for Malignant Mesothelioma Kills Cancer ‘From the Inside Out’
A new report suggests an anti-malaria drug called quinacrine has potential as a new pleural mesothelioma treatment. Before chloroquine became more popular, quinacrine was widely used to treat malaria. Now doctors mostly use it for a diarrhea disease caused by a parasite. But a report published in the International Journal of Molecular Science says quinacrine also has anti-cancer properties. Laboratory tests suggest it has the makings of a powerful new pleural mesothelioma treatment. The Challenge of Pleural Mesothelioma Malignant mesothelioma starts on the membranes around internal organs. It can quickly spread to other parts of the body. Pleural mesothelioma grows on the lining around the lungs. It is almost always caused by exposure to asbestos dust. Most people with mesothelioma … Continue reading Could Anti-Malaria Drug Become New Pleural Mesothelioma Treatment?